Related Experiment Video

Updated: Jun 27, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

Optimal duration of the antimicrobial treatment of ventilator-acquired pneumonia

Alexandros P Grammatikos1, Ilias I Siempos, Argyris Michalopoulos

  • 1Alfa Institute of Biomedical Sciences, Athens, Greece. agrammat@med.auth.gr

Expert Review of Anti-Infective Therapy
|December 5, 2008
PubMed

Insights

Short-course antimicrobial therapy (≤10 days) for ventilator-acquired pneumonia is as effective as longer durations. This approach did not increase mortality, ICU stay, or recurrence rates in most cases.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Clinical Pharmacy

Background:

  • Determining optimal antimicrobial therapy duration for ventilator-associated pneumonia (VAP) is crucial for patient outcomes and antibiotic stewardship.
  • Current guidelines often recommend 14-21 days, but evidence supporting shorter courses is limited.
  • The PneumA trial is one of the few studies directly comparing short (< or =10 days) versus long (14-21 days) therapy durations for VAP.

Purpose of the Study:

  • To evaluate the efficacy and safety of short-course antimicrobial treatment (≤10 days) compared to traditional long-course therapy (14-21 days) for patients with VAP.
  • To analyze existing trial data where antimicrobial treatment duration was a primary or secondary outcome measure.
  • To assess the impact of antimicrobial therapy duration on key clinical outcomes such as mortality, ICU length of stay, and recurrence rates.

Main Methods:

  • Systematic review and meta-analysis of identified clinical trials investigating antimicrobial treatment duration in VAP.
  • Inclusion criteria focused on trials reporting mortality, ICU length of stay, and recurrence rates in relation to treatment duration.
  • Analysis of data from nine relevant trials to estimate the association between short-term versus long-term antimicrobial administration.

Main Results:

  • Nine trials were identified and analyzed, with seven showing a statistically significant decrease in total antibiotic administration length.
  • Short-course antibiotic regimens (≤10 days) did not demonstrate adverse effects on patient mortality.
  • No significant differences were observed in ICU length of stay or VAP recurrence rates between short-course and long-course treatment groups.

Conclusions:

  • Available evidence supports the use of short-course antimicrobial treatments (≤10 days) for VAP, particularly when not caused by nonfermenting Gram-negative bacilli.
  • Shorter treatment durations can lead to reduced overall antibiotic exposure without compromising patient safety or clinical outcomes.
  • These findings have implications for antibiotic stewardship programs aiming to optimize VAP management and combat antimicrobial resistance.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...